[1] 薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介.临床肝胆病杂志, 2020, 36(6):34-37. [2] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020, 73(1):202-209. [3] Sharma P, Kumar A. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19. Diabetes Metab Syndr, 2020, 4(5):825-827. [4] Xu Z, Li H, Tian S, et al. Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease. J Hepatol, 2020, 73(5):1264-1265. [5] Hu F, Yang R, Huang Z, et al. 3Dmulti-echo dixon technique for simultaneous assessment of liver steatosis and iron overload in patients with chronic liver diseases: a feasibility study. Quant Imaging Med Surg, 2019, 9(6):1014-1024. [6] Zhan C, Olsen S, Zhang HC, et al. Detection of hepatic steatosis and iron content at 3 Tesla: comparison of two-point Dixon, quantitative multi-echo Dixon, and MR spectroscopy. Abdom Radiol (NY), 2019, 44(9):3040-3048. [7] Serai SD, Smith EA, Trout AT, et al. Agreement between manual relaxometry and semi-automated scanner-based multi-echo Dixon technique for measuring liver T2 in a pediatric and young adult population. Pediatr Radiol, 2018, 48(1):94-100. [8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186. [9] Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol, 2017,27(21):R1147-R1151. [10] Almazroo OA, Miah MK,Venkataramanan R. Drug metabolism in the liver. Clin Liver Dis, 2017, 21(1):1-20. [11] Ismaiel A, Dumitrascu DL. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review. Eur J Clin Invest, 2020, 50(10):e13331. [12] Gu Z, Bi Y, Yuan F, et al. FTO Polymorphisms are associated with metabolic dysfunction-associated fatty liver disease (MAFLD) Susceptibility in the older chinese han population. Clin Interv Aging, 2020, 15:1333-1341. [13] Smith A, BaumgartnerK, Bositis C. Cirrhosis: Diagnosis and management. Am Fam Physic, 2019, 100(12):759-770. [14] Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019, 156(5):1264-1281. [15] Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol, 2019, 70(3):531-544. [16] 邵幼林,范建高.非酒精性脂肪性肝病的流行现状与危害.中华肝脏病杂志,2019,27(1):10-13. [17] Jennison E, Patel J, Scorletti E, et al. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J, 2019, 95(1124):314-322. [18] Lugauer F, Nickel D, Wetzl J, et al. Accelerating multi-echo water-fat MRI with a joint locally low-rank and spatial sparsity-promoting reconstruction. MAGMA, 2017, 30(2):189-202. [19] Tang A, Tan J, Sun M, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology, 2013, 267: 422-431. [20] Middleton MS, Van Natta ML, Heba ER, et al. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology, 2018, 67:858-872. |